Abstract:Background. Prostate cancer (PC) is one of the most critical cancers affecting men’s health worldwide. The development of many cancers involves dysregulation or mutations in key transcription factors. This study established a transcription factor-based risk model to predict the prognosis of PC and potential therapeutic drugs. Materials and Methods. In this study, RNA-sequencing data were downloaded and analyzed using The Cancer Genome Atlas dataset. A total of 145 genes related to the overall survival rate of PC patients were screened using the univariate Cox analysis. The Kdmist clustering method was used to classify prostate adenocarcinoma (PRAD), thereby determining the cluster related to the transcription factors. The support vector machine-recursive feature elimination method was used to identify genes related to the types of transcription factors and the key genes specifically upregulated or downregulated were screened. These genes were further analyzed using Lasso to establish a model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used for the functional analysis. The TIMER algorithm was used to quantify the abundance of immune cells in PRAD samples. The chemotherapy response of each GBM patient was predicted based on the public pharmacogenomic database, Genomics of Drug Sensitivity in Cancer (GDSC, http://www.cancerrxgene.org). The R package “pRRophetic” was applied to drug sensitivity (IC50) value prediction. Results. We screened 10 genes related to prognosis, including eight low-risk genes and two high-risk genes. The receiver operating characteristic (ROC) curve was 0.946. Patients in the high-risk score group had a poorer prognosis than those in the low-risk score group. The average area under the curve value of the model at different times was higher than 0.8. The risk score was an independent prognostic factor. Compared with the low-risk score group, early growth response-1 (EGR1), CACNA2D1, AC005831.1, SLC52A3, TMEM79, IL20RA, CRACR2A, and FAM189A2 expressions in the high-risk score group were decreased, while AC012181.1 and TRAPPC8 expressions were increased. GO and KEGG analyses showed that prognosis was related to various cancer signaling pathways. The proportion of B_cell, T_cell_CD4, and macrophages in the high-risk score group was significantly higher than that in the low-risk score group. A total of 25 classic immune checkpoint genes were screened out to express abnormally high-risk scores, and there were significant differences. Thirty mutant genes were identified; in the high- and low-risk score groups, SPOP, TP53, and TTN had the highest mutation frequency, and their mutations were mainly missense mutations. A total of 36 potential drug candidates for the treatment of PC were screened and identified. Conclusions. Ten genes of both high-and low-risk scores were associated with the prognosis of PC. PC prognosis may be related to immune disorders. SPOP, TP53, and TTN may be potential targets for the prognosis of PC.

Identification of Critical Pathways and Hub Genes in TP53 Mutation Prostate Cancer by Bioinformatics Analysis

Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods

Identification of UBE2C As Hub Gene in Driving Prostate Cancer by Integrated Bioinformatics Analysis.

Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis

Identification of Pathologic and Prognostic Genes in Prostate Cancer Based on Database Mining

Identification of Candidate Hub Genes Correlated with the Pathogenesis, Diagnosis, and Prognosis of Prostate Cancer by Integrated Bioinformatics Analysis.

Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers

In‐silico identification of frequently mutated genes and their co‐enriched metabolic pathways associated with Prostate cancer progression

Comprehensive Analysis of Tumour Mutational Burden and Its Clinical Significance in Prostate Cancer

Role of Hub Genes in the Occurrence and Development of Testicular Cancer Based on Bioinformatics

Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer

Identification of key genes and pathways in castrate-resistant prostate cancer by integrated bioinformatics analysis

[Clinical Features and Prognostic Value of TP53 Mutation in Chinese Prostate Cancer Patients].

Identification of hub genes and their clinical value for predicting the development of prostate cancer from benign prostate hyperplasia by bioinformatic analysis

Key pathways in prostate cancer with SPOP mutation identified by bioinformatic analysis

Introduction of mutant TP53 related genes in metabolic pathways and evaluation their correlation with immune cells, drug resistance and sensitivity

Identification of hub genes predicting the development of prostate cancer from benign prostate hyperplasia and analyzing their clinical value in prostate cancer by bioinformatic analysis

Identification of the Key MicroRNAs and the miRNA-mRNA Regulatory Pathways in Prostate Cancer by Bioinformatics Methods

Four Novel Prognostic Genes Related to Prostate Cancer Identified Using Co-expression Structure Network Analysis

A Transcription Factor-Based Risk Model for Predicting the Prognosis of Prostate Cancer and Potential Therapeutic Drugs